AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Clinical trials for melanoma and ovarian cancer receive go-ahead.
2002 NOV 20 - (NewsRx.com & NewsRx.net) -- Avax Technologies, Inc., (NASDAQ:AVXT) announced that the U.S. Food and Drug Administration (FDA) has confirmed that there are no outstanding issues with regard to the company's investigational new drug (IND) applications for M-Vax and O-Vax, its AC Vaccine Technology candidates for the treatment of melanoma and ovarian cancers.
The company filed the applications on September 9, 2002, and the FDA has 30 days after the filing in which to request additional information before the applicant commences the clinical trial. The absence of outstanding issues at the end of the 30-day review period allows Avax to proceed with these clinical trials as planned.
David L. Tousley, Avax, stated, "We are pleased that we are now in a position, from a regulatory ...
- AVAX Technologies' AC Vaccine(TM) Data Presented at Hadassah Medical Center In...
- Press release article from: PR Newswire October 26, 1999 700+ words
...conducting a trial of the AC Vaccine in post-surgical breast...efficacious, and the AC Vaccine technology may prove...large, multicenter clinical trials and future commercialization...AVAX's proprietary AC Vaccine(TM) technology...
- AVAX Technologies Announces Collaboration with the University of Pennsylvania...
- Press release article from: Business Wire February 22, 2005 700+ words
...Company successfully completed clinical trials in ovarian cancer and renal cell...comprises the other 20%. About the AC Vaccine Therapeutic AVAX's AC Vaccine...product candidates. Previously clinical trials in ovarian and renal cell carcinoma...
- AVAX Technologies and Neptunus International Holdings Limited Announce Joint...
- Press release article from: PR Newswire June 15, 1999 700+ words
...commercialize our unique AC Vaccine technology outside of...the application of our AC Vaccine technology to other...Results from previous clinical trials of AVAX's unique vaccine...for the company's AC Vaccine technology in other...
- AVAX Technologies Announces the Commencement of Two Clinical Trials; Positive...
- Press release article from: Business Wire July 13, 2005 700+ words
...partner for the AC Vaccine in a number of...also planning clinical trials in France and...applicability of the AC Vaccine as a platform...treated with the AC Vaccine following surgery...Previously clinical trials in ovarian and...
- AVAX Technologies Announces Clearance to Commence Clinical Trials for Its...
- Press release article from: Business Wire December 16, 2004 700+ words
...programs with the AC Vaccine technology...in later stage clinical trials. Most importantly...SA. About the AC Vaccine Therapeutic AVAX...companies. AVAX's AC Vaccine is a therapeutic...earlier reported clinical trials in ovarian and...
- AVAX Advances Ovarian Cancer Program Corporate IND for O-VAX(TM) for the...
- Press release article from: PR Newswire January 18, 2000 700+ words
AVAX's AC Vaccine Technology Applied to...autologous cell vaccine (AC Vaccine(TM)) for the treatment...AVAX to begin Phase 2 clinical trials. Accordingly, AVAX has...We believe that the AC Vaccine technology is capable...
- AVAX Technologies Announces FDA Clearance to Commence Clinical Trials.
- Press release article from: PR Newswire October 10, 2002 700+ words
...Vax and O-Vax, its AC Vaccine Technology candidates for...AVAX to proceed with these clinical trials as planned. David L. Tousley...FDA concerning our planned clinical trials, and have refined our INDs...treating cancer patients in clinical trials and has satisfied ...
- AVAX Technologies' AC Vaccine(TM) Improves Relapse-Free Survival In a Breast...
- Press release article from: PR Newswire April 5, 2000 700+ words
...presentation of preclinical data on its AC Vaccine(TM) technology, an autologous cell...indicating that vaccination with AVAX's AC Vaccine technology resulted in improved relapse...modified with the hapten "DNP" (AVAX's AC Vaccine technology), compared to treatment...
Source: HighBeam Research, Clinical trials for melanoma and ovarian cancer receive go-ahead.